Skip to content

Assessment of atherosclerosis with 3 Tesla Magnetic Resonance Imaging: prevalence, progression and prognosis

Assessment of atherosclerosis with 3 Tesla Magnetic Resonance Imaging: prevalence, progression and prognosis - Assessment of atherosclerosis with 3T MRI

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38194
Enrollment
500
Registered
2012-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis vessel wall atheroma

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Patients with coronary artery disease, Transient Ischemic Attack (TIA), minor ischemic stroke, abdominal aortic aneurysm, peripheral arterial disease, presenting with symptoms suggestive of an acute coronary syndrome (ACS) and asymptomatic patients with an increased cardiovascular risk.

Exclusion criteria

Exclusion criteria: - pregnancy or possible pregnancy - documented allergic reaction to godalinium - patients with impaired renal fuction (GFR

Design outcomes

Primary

MeasureTime frame
1 .Prevalence and distribution of coronary and aortic atherosclerosis The prevalence of atherosclerosis is defined as the total number of atherosclerotic lesions in the coronary arteries and aorta on the baseline 3T MRI scan. 2. Progression (rate of changes) in coronary and aortic atherosclerosis Progression in atherosclerosis can express itself as an increase in the total number of atherosclerotic lesions, geometric measures or the proportion of the vessel wall area occupied by various plaque components. In this study all three variables of atherosclerosis will be used to assess the progression of atherosclerosis. 3. Coronary and aortic atherosclerosis to predict future events The baseline MRI scan will be used to predict future events. With respect to future events, information will be collected concerning non fatal and fatal vascular disease with clear definition.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)